Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Haldo, Navane, Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, Abilify), By Application- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Antipsychotic Drugs market size was estimated at USD 15.53 billion in 2022 and is expected to surpass around USD 26.7 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.4% during the forecast period 2022 to 2030.

Growth Factors:

Growing prevalence of psychosis and related diseases is driving the demand for antipsychotic drugs. The major factors contributing towards the growing incidence of these disorders include genetic mutations, substance-induced psychoses, and physical illness resulting in depression.

The introduction of newer antipsychotic compounds and huge investments for R&D are boosting the market growth. In addition, increasing efforts taken by the market players to expand therapeutic applications of these medicines are anticipated to create opportunities for the expansion of portfolio of antipsychotics in the near future, thereby fueling the demand.

Adverse effects such as insomnia, dry mouth, drowsiness, blurred vision, and probability of habit formation may have a harmful impact on a patient’s health. These effects are challenging the adoption of these drugs.

The patent expirations of key brands, such as Seroquel, Risperdal, Zyprexa, and Invega are restraining the growth of these brands. Moreover, players are introducing generic versions of antipsychotics and have begun investigating new therapeutic applications for these products; hence the generic products are slowly replacing the established brands in antipsychotic market.

Report Scope of the Antipsychotic Drugs Market

Report Coverage


Market Size

US$ 26.7 Billion by 2030

Growth Rate

CAGR of 8.4% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Product, application and Region,

Companies Mentioned

 Drive DeVilbissSidhil Ltd.; ALPS Mountaineering; SizeWise; LazerLazery; Sleepy Sleep; Restoration Goods; Bestway; Somnio LLC; American National Manufacturing, Inc.; Intex Development Co. Ltd.; WENZEL Group.

 Antipsychotic Drugs Market Trends

There have been changes in the R&D of antipsychotic drugs due to increasing awareness regarding the financial burden. This has led to the high demand for effective treatment for psychiatric illnesses. Thus, many pharmaceutical companies have launched long-acting injectables for antipsychotic drugs. Therefore, the benefits attributed to these long-acting injectables have led to greater adoption of these products leading to growth in the market.

Schizophrenia is a severe mental condition in which the patient faces abnormality in thinking, conduct, emotions, and sense of self. This condition can increase the chances of death if not treated properly. Therefore, many companies are focusing on developing new medications for the treatment of this condition. There are many FDA-approved medicines on the marketsuch as Chlorpromazine, Olanzapine, Aripiprazole, and other drugs approved each year, that are projected to boost market expansion throughout the projection period.

The overprescription of these medicines tends to have serious consequences as well as addiction. This condition is seen in people belonging to developed countries such as North America. This led to strict regulations by the government on these pharmaceuticals, therefore limiting the market growth.

Mental illnesses are becoming more common, imposing pressure on the healthcare system. As a result, the government is concentrating its efforts on increasing public knowledge of the illnesses and the effectiveness of the treatments used to cure them. As a result, there has been a significant increase in global demand for highly effective and safe drugs to treat persons with psychotic illnesses. In addition, the firms are focusing on the development of innovative antipsychotic injectable drugs that will help to eliminate the requirement for patients to be monitored for drug consumption. These factors are expected to provide good opportunities for the growth of the global antipsychotic drug market.

Furthermore, there has been a considerable shift toward telemedicine for the treatment of psychotic diseases during the COVID-19 pandemic. Many people's mental health suffered as a result of the lockdown and stay-at-home restrictions throughout the world. As a result, the usage of antipsychotic medicines to treat these symptoms has increased. Furthermore, during the pandemic, the global antipsychotic drugs market had a strong sales performance. This is also attributable to the pandemic's increasing usage of long-acting injectables.

Drug Class Insights

The antipsychotics are segmented into three classes: first generation, second generation, and third generation. The typical or standard antipsychotics were first-generation antipsychotic drugs developed in 1950s. However, drugs under this category pose risks such as blurred vision and drowsiness and some may have fatal effects. Thus, these products are expected to witness a negative growth over the forecast period, with availability of relatively more effective drugs with fewer adverse effects.

The second generation holds the largest share in the market. This class named as atypical antipsychotics includes clozapine, risperidone, sertindole, asenapne, olanzapine, paliperidone, quetiapine. These are used for treatment of schizophrenia and have quickly begun replacing the older, first-generation antipsychotics.

The third generation, aripiprazole (Abilify) is indicated for the treatment of schizophrenia and is also used as maintenance therapy for this disease. The clinical advantages of safety and tolerability of aripiprazole contribute to the segment’s growth. Thus, it is expected to be the fastest growing segment with a CAGR of over 2.4% in the forecast period. 

Application Insights

The antipsychotics are used in treating schizophrenia, different types of bipolar disorders, major depression (unipolar), dementia, and other psychotic disorders. These products have first-line therapeutic applications during treatment and maintenance phases of schizophrenia. The etiology of schizophrenia is still unknown; thus the treatment primarily aims at eliminating the symptoms of the disease. Application of antipsychotics in treating schizophrenia accounts for the largest revenue share.

Furthermore, there is growing detection of unipolar disorder, which is a type of major depression, since the past decade owing to rising awareness regarding the disorder and available treatments. Thus, this segment is anticipated to grow at the fastest rate.

Regional Insights

North America dominated the market by capturing the largest revenue share in 2015. According to the Anxiety and Depression Association of America, about 6.7% of the U.S. population aged 18 years and above was suffering from major depression in 2016. Many people with physical illnesses suffer from co-occurring disorders. Increasing prevalence of mental health disorders, such as schizophrenia and bipolar disorder, is driving the antipsychotics demand in North America.

Asia Pacific is expected to exhibit the fastest growth in the near future due to rising social awareness regarding psychotic disorders and other associated disorders, such as bipolar (mania), anxiety, and major depression. Also, growing access and availability of medicines for treatment and management of the symptoms of mental illnesses is expected to drive the growth of the Asia Pacific market.

Recent Developments

  • In Feb 2022, Alkermes plc, a global pharmaceutical company, announced positive results from ENLIGHTEN-early, a phase 3b study that evaluate the study of LYBALVI in patient's early illness
  • In Jan 2022, Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka American Pharmaceutical, Inc. and Lundbeck, Inc., announced that the U.S. FDA  has approved the supplemental new drug application of REXULTI®  for Schizophrenia in 13 to 17-year-old patients.
  • In Feb 2021, Dr. Reddy’s Laboratories Ltd., a pharmaceutical company, launched Fluphenazine Hydrochloride tablets. The medication is used to treat the symptoms of psychotic disorders.

Some of the prominent players in the Antipsychotic Drugs Market include:  Drive DeVilbissSidhil Ltd.; ALPS Mountaineering; SizeWise; LazerLazery; Sleepy Sleep; Restoration Goods; Bestway; Somnio LLC; American National Manufacturing, Inc.; Intex Development Co. Ltd.; WENZEL Group.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antipsychotic Drugs market

  • Drug Class
    • First Generation
    • Second Generation
    • Third Generation
  • Application
    • Schizophrenia
    • Bipolar disorder
    • Unipolar depression
    • Dementia
    • Others

By Geography

North America

  • U.S.
  • Canada


  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Points Covered in Antipsychotic Drugs Market Study:

  • Growth of Antipsychotic Drugs in 2022
  • Market Estimates and Forecasts (2017-2030)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Antipsychotic Drugs and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Antipsychotic Drugs Consumption Analysis
  •  Antipsychotic Drugs Production Analysis
  •  Antipsychotic Drugs and Management